Market news

Built on substance, not hype, Teva's mega rally is just getting started.

Teva Pharmaceutical (TEVA) is entering a strong growth phase despite near-term concerns around Auste

Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference. Francis said the company achieved the miles

Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operat

New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD) in patients aged ≥55 yearsAcross all four patient profiles, AUSTEDO® (deutetrabenazine) was most closely related to the attributes most valued by healthcare providersThese findings from Teva detail specific healthcare provider preferences around tolerability and efficacy, while

In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-'749 for ≥ 6 months met criteria for remission Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-'749 from existing regimens Ahead of the Q4 FDA anticipated approval decision, the growing bod

Options traders are targeting FPS, TEVA, and AFL

Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility. Speaking at

Teva Begins Trading Ordinary Shares Directly on the NYSE Teva Pharmaceutical Industries Ltd Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global biopharmaceutical company, today announced that its ordinary shares will begin trading today directly on the New York Stock Exchange (NYSE) completing the compan

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s assets in a transaction valued at up to $125 million. The deal is structured as an upfront payment of $57.5 million followed by up to an additional $67.5 million in conditional milestone payments. Teva will […]

Public Advisory - Generic acetaminophen by Teva recalled because it may contain foreign material

Here are the biggest calls on Wall Street on Wednesday.

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro Notes”) and Teva Pharmaceutical Finance Netherlands III B.V. (“Teva Finance III”) and Teva Pharmaceutical Finance Netherlands IV B.V. (“Teva Finance IV”

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]

TEL AVIV, Israel, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to BBB- from BB+, with a Stable outlook. With this upgrade, along with the other recent upgrades from Fitch and Moody’s, Teva now has investment-grade credit ratings from all the agencies which cover its debt. Eli Kalif, Teva's Chief Financial Officer, commented: “Teva’s trio of rating upg

Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.

While Teva announced positive Phase II data, it has not yet confirmed Phase III plans.

Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key me

Teva Pharmaceutical (TEVA) stock gains as the company succeeds in a mid-stage trial for its celiac disease therapy developed with Royalty Pharma (RPRX). Read more here.

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at three upcoming investor conferences in September as follows: Morgan Stanley 24th Annual Global Healthcare ConferenceMonday, September 14, 2026, at 8:30 A.M. Eastern Time (ET)J.P. Morgan U.S. All Stars Conference Tuesday, September 22, 2026, at 8:00 A.M. British Summer Time (3:00 A.M. ET)BofA Global Healthcar

The string of deals builds on the Trump administration's push to link the nation's drug prices to cheaper ones abroad.

TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.